Pleckstrin homology domain-interacting protein (PHIP) as a marker and mediator of melanoma metastasis

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 18, 2012, Pages 7067-7072

  De Semir, David ^a,c   Nosrati, Mehdi ^a,c   Bezrookove, Vladimir ^a,c   Dar, Altaf A ^a,c   Federman, Scot ^a   Bienvenu, Geraldine ^a   Venna, Suraj ^a,g   Rangel, Javier ^a   Climent, Joan ^b,h   Meyer Tamgüney, Tanja M ^b   Thummala, Suresh ^a,c   Tong, Schuyler ^c   Leong, Stanley P L ^c,d   Haqq, Chris ^d   Billings, Paul ^e,f   Miller III, James R ^a,c   Sagebiel, Richard W ^a,c   Debs, Robert ^c   Kashani Sabet, Mohammed ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e Life Technologies Inc   (United States)

^f Melanoma Diagnostics Inc   (United States)

^g WASHINGTON CANCER INSTITUTE   (United States)

^h Instituto Universitario IVI INCLIVA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; BETA CATENIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLECKSTRIN; PLECKSTRIN HOMOLOGY DOMAIN INTERACTING PROTEIN; RAS PROTEIN; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INVASION; CANCER PROGNOSIS; CANCER SURVIVAL; CHROMOSOME 6Q; CHROMOSOME LOSS; CONTROLLED STUDY; FEMALE; GENE DOSAGE; GENE LOCUS; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MELANOMA METASTASIS; METASTASIS POTENTIAL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR BIOPSY; WILD TYPE;

ANIMALS; BASE SEQUENCE; CELL LINE, TUMOR; FEMALE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MELANOMA; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, NUDE; NERVE TISSUE PROTEINS; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

MURINAE; MUS;

EID: 84860794312     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1119949109     Document Type: Article

References (31)

1. Chapman PB, et al.; BRIM-3 Study Group (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507-2516.
2. Baserga R (2009) Customizing the targeting of IGF-1 receptor. Future Oncol 5:43-50.
3. Hofmann F, García-Echeverría C (2005) Blocking the insulin-like growth factor-I receptor as a strategy for targeting cancer. Drug Discov Today 10:1041-1047. (Pubitemid 41074142)
4. Manning BD, Cantley LC (2007) AKT/PKB signaling: Navigating downstream. Cell 129: 1261-1274. (Pubitemid 46962095)
5. Podcheko A, et al. (2007) Identification of a WD40 repeat-containing isoform of PHIP as a novel regulator of beta-cell growth and survival. Mol Cell Biol 27:6484-6496. (Pubitemid 47435753)
6. Li S, et al. (2010) The full-length isoform of the mouse pleckstrin homology domain-interacting protein (PHIP) is required for postnatal growth. FEBS Lett 584:4121-4127.
7. Haqq C, et al. (2005) The gene expression signatures of melanoma progression. Proc Natl Acad Sci USA 102:6092-6097. (Pubitemid 40594260)
8. Sakamoto S, McCann RO, Dhir R, Kyprianou N (2010) Talin1 promotes tumor invasion and metastasis via focal adhesion signaling and anoikis resistance. Cancer Res 70: 1885-1895.
9. Rangel J, et al. (2006) Prognostic significance of nuclear receptor coactivator-3 over-expression in primary cutaneous melanoma. J Clin Oncol 24:4565-4569. (Pubitemid 46630952)
10. Balch CM, et al. (2009) Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27:6199-6206.
11. Bauer J, Bastian BC (2006) Distinguishing melanocytic nevi from melanoma by DNA copy number changes: Comparative genomic hybridization as a research and diagnostic tool. Dermatol Ther 19:40-49.
12. Blokx WA, van Dijk MC, Ruiter DJ (2010) Molecular cytogenetics of cutaneous melanocytic lesions - diagnostic, prognostic and therapeutic aspects. Histopathology 56: 121-132.
13. Dankort D, et al. (2009) Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet 41:544-552.
14. Tsao H, Goel V, Wu H, Yang G, Haluska FG (2004) Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. J Invest Dermatol 122:337-341. (Pubitemid 38281053)
15. Damsky WE, et al. (2011) β-catenin signaling controls metastasis in Braf-activated Pten-deficient melanomas. Cancer Cell 20:741-754.
16. Dillon RL, Muller WJ (2010) Distinct biological roles for the akt family in mammary tumor progression. Cancer Res 70:4260-4264.
17. Arboleda MJ, et al. (2003) Overexpression of AKT2/protein kinase Bbeta leads to up-regulation of beta1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells. Cancer Res 63:196-206. (Pubitemid 36070440)
18. Sachdev D, Zhang X, Matise I, Gaillard-Kelly M, Yee D (2010) The type I insulin-like growth factor receptor regulates cancer metastasis independently of primary tumor growth by promoting invasion and survival. Oncogene 29:251-262.
19. Govindarajan B, et al. (2007) Overexpression of Akt converts radial growth melanoma to vertical growth melanoma. J Clin Invest 117:719-729. (Pubitemid 46348530)
20. Meier F, et al. (2005) The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma. Front Biosci 10: 2986-3001. (Pubitemid 40910537)
21. Ramaswamy S, et al. (1999) Regulation of G1 progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/Akt pathway. Proc Natl Acad Sci USA 96:2110-2115. (Pubitemid 29117876)
22. Ross DT, et al. (2000) Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet 24:227-235. (Pubitemid 30132189)
23. Villanueva J, et al. (2010) Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 18:683-695.
24. Miele ME, et al. (2000) A human melanoma metastasis-suppressor locus maps to 6q16.3-q23. Int J Cancer 86:524-528. (Pubitemid 30249733)
25. Kashani-Sabet M, et al. (2002) Identification of gene function and functional pathways by systemic plasmid-based ribozyme targeting in adult mice. Proc Natl Acad Sci USA 99:3878-3883. (Pubitemid 34252199)
26. Kononen J, et al. (1998) Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4:844-847. (Pubitemid 28331029)
27. Kashani-Sabet M, et al. (2004) NF-kappa B in the vascular progression of melanoma. J Clin Oncol 22:617-623.
28. Wiegant J, Raap AK (2001) Probe labeling and fluorescence in situ hybridization. Curr Protoc Cytom 8:8.3.
29. Chin SF, et al. (2003) A simple and reliable pretreatment protocol facilitates fluorescent in situ hybridisation on tissue microarrays of paraffin wax embedded tumour samples. Mol Pathol 56:275-279.
30. Munné S, Márquez C, Magli C, Morton P, Morrison L (1998) Scoring criteria for preimplantation genetic diagnosis of numerical abnormalities for chromosomes X, Y, 13, 16, 18 and 21. Mol Hum Reprod 4:863-870. (Pubitemid 28430649)
31. Van Raamsdonk CD, et al. (2009) Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 457:599-602.